Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Dr. Hoenle AG ( (DE:HNL) ) is now available.
Dr. Hönle AG has adjusted its financial forecast for the fiscal year 2024/25, anticipating revenues between €92 million and €94 million, down from the previous year’s €98.7 million. Despite the lower revenue expectations, the company projects an operating result before depreciation and amortization (EBITDA) between €5 million and €6 million, thanks to cost-cutting measures. This adjustment reflects the company’s strategic response to current market conditions and aims to maintain operational efficiency, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (DE:HNL) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.
More about Dr. Hoenle AG
Dr. Hönle AG is a listed technology company based in Gilching, specializing in innovative solutions with a focus on UV technology for various industrial applications. The company develops and sells industrial adhesives, adhesive curing devices, drying systems for the printing and coating industry, and environmentally friendly disinfection solutions for water, air, and surfaces. With 600 employees, the Hönle Group serves global market leaders and operates in over 20 countries through its own and partner companies.
Average Trading Volume: 6,222
Technical Sentiment Signal: Sell
Current Market Cap: €57.83M
See more data about HNL stock on TipRanks’ Stock Analysis page.